P2Et (Caesalpinia spinosa extract)

DRUG2 trials

Sponsors

Hospital Universitario San Ignacio

Conditions

Breast CancerCOVIDCOVID19Coronavirus InfectionQuality of LifeSARS-CoV 2Tumor, Breast

Phase 2

P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19

Hospital Universitario San IgnacioCoronavirus Infection, COVID, COVID19 +1

Start: 2020-09-30End: 2021-11-30Target: 100Updated: 2021-08-10

Safety and Efficacy Evaluation of the P2Et Extract in Patients With Breast Cancer

Hospital Universitario San IgnacioBreast Cancer, Quality of Life, Tumor, Breast

Start: 2022-03-01End: 2023-06-30Target: 58Updated: 2022-08-09

Related Papers

Safety and efficacy of P2Et extract from Caesalpinia spinosa in breast cancer patients: study protocol for a randomized double blind phase II clinical trial (CS003-BC).

2023-09-052 citations

Randomized double-blind clinical study in patients with COVID-19 to evaluate the safety and efficacy of a phytomedicine (P2Et)

Frontiers in Medicine2022-09-0813 citations